Vapreotide

Drug Profile

Vapreotide

Alternative Names: BMY-41606; Debio 8609; Docrised; RC-160; Sanvar; Sanvar IR; Sanvar SR

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator Tulane University
  • Developer Debiovision; Salix Pharmaceuticals
  • Class Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal varices
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acromegaly; Crohn's disease; Diarrhoea; Neuroendocrine tumours; Oesophageal varices
  • Discontinued Breast cancer; Carcinoid tumour; Liver cancer; Prostate cancer

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 04 Nov 2008 Preregistration for Oesophageal varices in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top